StockSelector.com
  Research, Select, & Monitor Tuesday, October 27, 2020 8:35:22 PM ET  
Trade Ideas The Market Industries Stocks Portfolio

 
Ticker Lookup
American Bio Medica Corporation$0.24$.014.35%

  Quote | Ranking | Chart | Valuations | Sentiment | Industry | News | Earnings | Analysts | More...

Your Target?

 ABMC Reports Third Quarter 2017 Results
   Tuesday, November 14, 2017 10:00:23 AM ET

American Bio Medica Corporation (OTCPK: ABMC) today announced financial results for the three and nine months ended September 30, 2017.

Chief Executive Officer Melissa A. Waterhouse stated, "Although the third quarter of 2017 represented a decrease in sales when compared to the third quarter of 2016, sales actually increased when compared to the first and second quarter of 2017. As of result of OTC marketing clearance for our Rapid TOX Cup II in mid-August 2017, we are working on a number of sales opportunities that we are hopeful will offset the sales declines due to the loss of government accounts (accounts that are the subject of our ongoing litigation) and contract manufacturing sales. From an operational standpoint, we are continually reviewing our expenses and resources to ensure we are utilizing them for maximum benefit and to ensure expenses stay in line with sales."

Financial Highlights

-- Net sales in the third quarter of 2017 were $1,354,000, compared to $1,417,000 in the third quarter 2016, a decrease of 4.4%. Net sales in the nine months ended September 30, 2017 were $3,975,000, compared to $4,392,000 in the nine months ended September 30, 2016, a decrease of 9.5%. The loss of a government account in the fourth quarter of 2016 and the anticipated decrease in contract manufacturing sales were the primary cause of the reduced sales in both periods. However, these declines were partially offset by increased international and national account sales in both periods.

-- Operating income was $5,000 in the third quarter of 2017, compared to an operating loss of $60,000 in the third quarter of 2016. Operating expenses decreased 16.4% in the third quarter of 2017 when compared to the third quarter 2016. We saw reductions in R&D expense (7.1%) and selling and marketing expenses (42.2%), while G&A expense increased slightly (2.2%) due to litigation we initiated earlier in 2017.

-- Operating loss was $83,000 in the nine months ended September 30, 2017, compared to an operating loss of $118,000 in the nine months ended September 30, 2016. Operating expenses declined 14.0% in the nine months ended September 30, 2017 compared to the nine months ended September 30, 2016. Reductions in R&D (30.9%) and selling and marketing expense (35.7%) were partially offset by increased G&A costs (4.3%), again due to litigation. In addition, the nine months ended September 30, 2016 included other income of $200,000 primarily related to a tech transfer that did not recur in the nine months ended September 30, 2017.

-- Net loss was $49,000 in the third quarter of 2017, compared to net loss of $88,000 in the third quarter of 2016. Net loss was $252,000 in the nine months ended September 30, 2017, compared to net loss of $130,000 in the nine months ended September 30, 2016.

For more information on ABMC or its drug testing products, please visit www.abmc.com.

About American Bio Medica Corporation

American Bio Medica Corporation manufactures and markets accurate, cost-effective immunoassay test kits, primarily point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC’s Rapid Drug Screen(R), Rapid ONE(R), RDS(R) InCup(R), Rapid TOX(R) and Rapid TOX Cup(R) II test for the presence or absence of drugs of abuse in urine, while OralStat(R) tests for the presence or absence of drugs of abuse in oral fluids. ABMC’s Rapid Reader(R) is a compact, portable device that, when connected to any computer, interprets the results of an ABMC drug screen, and sends the results to a data management system, enabling the test administrator to easily manage their drug testing program.

This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, risks and uncertainties related to the following: continued acceptance of our products, increased levels of competition in our industry, acceptance of new products, product development, compliance with regulatory requirements, including but not limited to our ability to obtain marketing clearance on our product for our intended markets, intellectual property rights, our dependence on key personnel, third party sales and suppliers, trading in our common shares may be subject to "penny stock" rules, our history of recurring net losses and our ability to continue as a going concern. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results. Investors are strongly encouraged to review the section entitled "Risk Factors" in the Company’s annual report on Form 10-K for the year ended December 31, 2016, quarterly reports on Form 10-Q, and other periodic reports on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company’s common shares.

(financial tables follow)

 
                                                                                                                                                 AMERICAN BIO MEDICA CORPORATION
                                                                                                                                               Condensed Statements of Operations
                                                                                                                                                           (unaudited)
                                                                                               For the three                        For the three                        For the nine                            For the nine
                                                                                                                                     months ended                                            months ended                                            months ended                                               months ended
                                                                                                                  September 30,     September 30,     September 30,        September 30,
                                                                                                                                         2017                                                    2016                                                    2017                                                       2016
                                                                                                               -------------------- ------------- -------------------- -------------------- ------------- -------------------- -------------------- ------------- -------------------- -------------------- --------------------
                                                                                                                                                                                                                                                                                                             
Net sales                                                                                                                         $     1,354,000                                         $     1,417,000                                         $     3,975,000                                         $            4,392,000
Cost of goods sold                                                                                                     788,000           806,000         2,279,000                2,441,000
                                                                                                               -------------------- ------------- -------------------- -------------------- ------------- -------------------- -------------------- ------------- -------------------- -------------------- --------------------
   Gross profit                                                                                                        566,000           611,000         1,696,000                1,951,000
                                                                                                               -------------------- ------------- -------------------- -------------------- ------------- -------------------- -------------------- ------------- -------------------- -------------------- --------------------
                                                                                                                                                                                                                                                                                                             
Operating expenses:
   Research and development                                                                                                                26,000                                                  28,000                                                  94,000                                                        136,000
   Selling and marketing                                                                                                                  159,000                                                 275,000                                                 531,000                                                        827,000
   General and administrative                                                                                          376,000           368,000         1,154,000                1,106,000
                                                                                                               -------------------- ------------- -------------------- -------------------- ------------- -------------------- -------------------- ------------- -------------------- -------------------- --------------------
      Total operating expenses                                                                                         561,000           671,000         1,779,000                2,069,000
                                                                                                               -------------------- ------------- -------------------- -------------------- ------------- -------------------- -------------------- ------------- -------------------- -------------------- --------------------
                                                                                                                                                                                                                                                                                                             
Operating income / (loss)                                                                                                5,000          (60,000)          (83,000)                (118,000)
                                                                                                               -------------------- ------------- -------------------- -------------------- ------------- -------------------- -------------------- ------------- -------------------- -------------------- --------------------
                                                                                                                                                                                                                                                                                                             
Other (expense)/ income                                                                                               (56,000)          (27,000)         (170,000)                 (10,000)
                                                                                                               -------------------- ------------- -------------------- -------------------- ------------- -------------------- -------------------- ------------- -------------------- -------------------- --------------------
                                                                                                                                                                                                                                                                                                             
Net loss before tax                                                                                                                      (51,000)                                                (87,000)                                               (253,000)                                                      (128,000)
                                                                                                                                                                                                                                                                                                             
Income tax benefit / ( expense)                                                                                          2,000           (1,000)             1,000                  (2,000)
                                                                                                               -------------------- ------------- -------------------- -------------------- ------------- -------------------- -------------------- ------------- -------------------- -------------------- --------------------
                                                                                                                                                                                                                                                                                                             
Net loss                                                                                                                          $      (49,000)                      $      (88,000)                      $     (252,000)                      $            (130,000)
                                                                                                               ==================== ============= ==================== ==================== ============= ==================== ==================== ============= ==================== ==================== ====================
                                                                                                                                                                                                                                                                                                             
Basic & diluted loss per common share                                                                                             $        (0.00)                      $        (0.00)                      $        (0.01)                      $               (0.01)
                                                                                                               ==================== ============= ==================== ==================== ============= ==================== ==================== ============= ==================== ==================== ====================
                                                                                                                                                                                                                                                                                                             
Weighted average shares outstanding - basic and diluted                                                29,297,333        27,284,308        29,129,168               27,056,216
                                                                                                               ==================== ============= ==================== ==================== ============= ==================== ==================== ============= ==================== ==================== ====================
                                                                                                                                                                                                                                                                                                             

(Condensed Balance Sheets follow)

 
                                                                         American Bio Medica Corporation
                                                                            Condensed Balance Sheets
                                                                               September 30,          December 31,
                                                                                                                         2017                                      2016
                                                                                                                      (unaudited)
                                                                                                                    -------------                          --------------------
                                ASSETS
Current Assets
   Cash and cash equivalents                                                                                      $       150,000                        $              156,000
   Accounts receivable, net of allowance for doubtful accounts of                                                         521,000                                       556,000
   $51,000 at September 30, 2017 and $49,000 at December 31, 2016
   Inventory, net of allowance of $453,000 at September 30, 2017 and                                                    1,462,000                                     1,582,000
   $449,000 at December 31, 2016
   Prepaid expenses and other current assets                                                                               49,000                                        92,000
                                                                                                                    -------------                          --------------------
Total current assets                                                                                                    2,182,000                                     2,386,000
Property, plant and equipment, net                                                                                        810,000                                       824,000
Patents, net                                                                                                              107,000                                        93,000
Other assets                                                                                                               21,000                                        21,000
Deferred finance costs - line of credit, net                                                                  23,000                                        47,000
                                                                                                                    -------------                          --------------------
Total assets                                                                                                      $     3,143,000                        $            3,371,000
                                                                                                                    =============                          ====================
    LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
   Accounts payable                                                                                               $       306,000                        $              304,000
   Accrued expenses and other current liabilities                                                                         287,000                                       276,000
   Wages payable                                                                                                          257,000                                       299,000
   Line of credit                                                                                                         580,000                                       639,000
   Current portion of long-term debt                                                                                       87,000                                        75,000
                                                                                                                    -------------                          --------------------
Total current liabilities                                                                                               1,517,000                                     1,593,000
Long-term debt, net of current portion and deferred finance costs                                                         748,000                                       753,000
Other long-term liabilities                                                                                                22,000                                             0
                                                                                                                    -------------                          --------------------
Total liabilities                                                                                                       2,287,000                                     2,346,000
                     COMMITMENTS AND CONTINGENCIES
Stockholders’ Equity:
   Common stock                                                                                                           293,000                                       288,000
   Additional paid-in capital                                                                                          21,115,000                                    21,037,000
   Accumulated deficit                                                                                                (20,552000)                                  (20,300,000)
                                                                                                                    -------------                          --------------------
Total stockholders’ equity                                                                     856,000                                     1,025,000
                                                                                                                    -------------                          --------------------
Total liabilities and stockholders’ equity                                             $     3,143,000                        $            3,371,000
                                                                                                                    =============                          ====================
                                                                                                                                                            

http://cts.businesswire.com/ct/CT?id=bwnews&sty=20171114005276r1&sid=cmtx6&distro=nx&lang=en

View source version on businesswire.com: http://www.businesswire.com/news/home/20171114005276/en/

SOURCE: American Bio Medica Corporation

ABMC 
Melissa A. Waterhouse, 800-227-1243, Ext 107 
Chief Executive Officer


Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results

StockSelector.com, the StockSelector.com logo, and News Selects are trademarks of StockSelector.com.
Copyright © 1998 - 2020 StockSelector.com. All rights reserved.